|
Market Closed -
Nasdaq
16:00:00 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 1.550 USD | +6.16% |
|
+13.14% | -14.84% |
| 08-04 | Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending | CI |
| 07-22 | Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 | CI |
Company Valuation: Alzamend Neuro, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 7.427 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 71.23% |
| Enterprise Value (EV) | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 7.427 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 71.23% |
| P/E | -7.29x | -3.65x | -0.48x | -0.52x | -0.43x | -0.6x |
| PBR | 7.3x | - | -1.85x | - | 6.62x | -0.6x |
| PEG | - | -0.51x | 0x | 0x | 0x | 0.53x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.69x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.69x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -189 | -202.5 | -132.3 | -11.32 | -2.63 | -2.6 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | -7.907 | -11.26 | -8.931 | -4.121 | -7.949 | -10.7 |
| EBIT 1 | -12.32 | -14.87 | -9.938 | -4.497 | -8.767 | -10.8 |
| Net income 1 | -12.36 | -14.88 | -9.948 | -5.105 | -8.772 | -10.8 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 1,377.000 | 738.855 | 63.990 | 5.940 | 1.140 | 1.550 |
| Nbr of stocks (in thousands) | 68.9 | 71.8 | 76.3 | 734 | 3,805 | 4,792 |
| Announcement Date | 7/19/22 | 7/27/23 | 7/30/24 | 7/22/25 | 7/22/26 | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.6x | - | - | - | 7.43M | |
| 33.04x | 5.91x | 17.56x | 0.97% | 48.42B | |
| -21.14x | 288.75x | -21.43x | -.--% | 43.66B | |
| 45.52x | 5.25x | 28.69x | -.--% | 39.51B | |
| 30.48x | 3.03x | 13.08x | -.--% | 38.95B | |
| 30.58x | 8.82x | 22.17x | 0.38% | 32.61B | |
| 32.9x | 5.38x | 24.45x | -.--% | 16.15B | |
| 23.48x | 2.05x | 8.89x | 1.15% | 14.16B | |
| 74.93x | 3.96x | 15.35x | -.--% | 13.37B | |
| Average | 27.69x | 40.39x | 13.59x | 0.31% | 27.43B | |
| Weighted average by Cap. | 26.43x | 55.41x | 12.18x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZN Stock
- Valuation Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
